var title_f15_57_16272="Short axis rheumatic MR";
var content_f15_57_16272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatic mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view during diastole (D) shows a mildly stenotic mitral orifice (MVO) by area (4 cm2), which presented no significant obstruction to mitral inflow. The valve is shown during systole in the lower panel (arrows). The medial side of the valve has failed to coapt; in rheumatic mitral regurgitation, failure of coaptation of this degree is usually associated with significant mitral regurgitation.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16272=[""].join("\n");
var outline_f15_57_16272=null;
var title_f15_57_16273="Suspicion Index tool for NPD-C";
var content_f15_57_16273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F85656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F85656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Suspicion Index tool for Niemann-Pick disease type C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 514px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symptoms are scored according to their relative association with positive Niemann-Pick disease type C (NPD-C) diagnosis. The combination of symptoms and the patient's family history together provide the prediction score.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wijburg FA, Sedel F, Pineda M, et al. Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 2012; 78:1560. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16273=[""].join("\n");
var outline_f15_57_16273=null;
var title_f15_57_16274="Port placement right adrenalectomy";
var content_f15_57_16274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Port placement right adrenalectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peritoneal cavity is accessed with a Veres technique through a midclavicular, subcostal site. Three additional 5 mm ports are placed that include a flank port in the mid-axillary line between the subcostal margin and the iliac crest, an epigastric port and a medial subcostal port. One additional port may be needed to retract the liver. Once the adrenal gland is resected, it is captured in a laparoscopic bag that is placed through the 12 mm subcostal port site and removed by extending this incision, as needed.",
"    <div class=\"footnotes\">",
"     * Port placement and technique may vary amongst laparoscopic surgeons.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16274=[""].join("\n");
var outline_f15_57_16274=null;
var title_f15_57_16275="Subcapsular liver hematoma on MR";
var content_f15_57_16275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Subcapsular liver hematoma on MR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These&nbsp;magnetic resonance (MR)&nbsp;images&nbsp;are from a patient with HELLP syndrome and a subcapsular liver hematoma. (A) The T2 weighted image shows a 9 mm hyperintense focus (arrow) that could represent a small laceration or a hepatic cyst. (B) The T1 weighted image shows an adjacent subcapsular hematoma (arrowhead) with both hyperintense and hypointense components reflecting a complex solid thrombus. The subcapsular hematoma was estimated as occupying less than 10 percent of the liver surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16275=[""].join("\n");
var outline_f15_57_16275=null;
var title_f15_57_16276="Typical form episcleritis";
var content_f15_57_16276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F87224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F87224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical form with sectoral injection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16276=[""].join("\n");
var outline_f15_57_16276=null;
var title_f15_57_16277="Cervical dilators";
var content_f15_57_16277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Cervical dilators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Pratt dilator. (B) Hegar dilator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16277=[""].join("\n");
var outline_f15_57_16277=null;
var title_f15_57_16278="Nerve biopsy";
var content_f15_57_16278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neuronal loss in vasculitic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nerve infarction in vasculitic neuropathy leads to dropout of neural axons. The biopsy on the left is from a normal nerve. The biopsy on the right shows extensive neuronal loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16278=[""].join("\n");
var outline_f15_57_16278=null;
var title_f15_57_16279="Nail psoriasis oil drop";
var content_f15_57_16279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66374%7EDERM%2F70962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66374%7EDERM%2F70962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oil drop sign and distal onycholysis in psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discoloration of the nail plate and distal onycholysis (separation of the nail plate from the nail bed) are present in this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail pits in psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous pits are present on the nail of this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16279=[""].join("\n");
var outline_f15_57_16279=null;
var title_f15_57_16280="Treatment of recurrent and metastatic nasopharyngeal carcinoma";
var content_f15_57_16280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Edwin P Hui, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Anthony TC Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Quynh-Thu Le, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16280/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/57/16280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma arises from the lining of the nasopharynx, the narrow tubular passage behind the nasal cavity. Worldwide, there are 80,000 incident cases and 50,000 deaths annually, but there is remarkable variation in racial and geographic distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/1\">",
"     1",
"    </a>",
"    ]. While rare in most parts of the world, nasopharyngeal carcinoma is endemic in southern China, southeast Asia, north Africa, and the arctic, where undifferentiated, nonkeratinizing squamous cell carcinoma is the predominant histology.",
"   </p>",
"   <p>",
"    The treatment of residual, recurrent, and metastatic nasopharyngeal cancer is presented here. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is staged according to the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/2\">",
"     2",
"    </a>",
"    ]. The World Health Organization (WHO) classifies nasopharyngeal carcinoma into three histopathologic types [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Keratinizing squamous cell carcinoma (WHO Type I)",
"     </li>",
"     <li>",
"      Nonkeratinizing carcinoma: differentiated (WHO Type II) and undifferentiated (WHO Type III)",
"     </li>",
"     <li>",
"      Basaloid squamous cell carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Staging and the histopathologic classification of nasopharyngeal carcinoma are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LOCOREGIONAL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the treatment for locoregional recurrence of nasopharyngeal carcinoma include reirradiation or nasopharyngectomy. The location of the nasopharynx, its proximity to vital organs, the high radiation doses given for primary therapy, and chemotherapy and radiation resistance induced by previous therapy make retreatment challenging.",
"   </p>",
"   <p>",
"    The stage at the time of recurrence (rTNM) and the interval between the initial treatment and recurrence are important prognostic factors (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Patients with a brief disease-free interval between completion of initial therapy and diagnosis of recurrent disease and those with advanced recurrent T-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    N-stage may be best treated with palliative chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A carefully selected subset of patients do achieve long-term survival when managed with salvage surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reirradiation. Prior to treatment, a thorough evaluation for concomitant distant metastases is needed because approximately half of patients with apparent local recurrence have synchronous distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Salvage surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngectomy is an option for patients with small local recurrences and no distant metastases. Surgery in this setting is technically challenging; the goal is to achieve an adequate margin while preserving the neurovascular bundle and restoring critical mucosal barriers. While anterior approaches are most commonly used, endoscopic nasopharyngectomy in selected patients may achieve comparable results with reduced complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-year survival rates as high as 60 percent after salvage surgery have been reported for carefully selected patients, but a survival benefit may be restricted to those with T1 or T2 recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In addition to high T stage (with skull base, dural, or brain involvement) (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ), positive surgical margins, and concurrent nodal metastases have been associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radical, modified radical, or selective neck dissection is indicated for residual nodal disease after initial RT or for an isolated neck recurrence.",
"   </p>",
"   <p>",
"    Adjuvant chemotherapy and postoperative radiation therapy (RT), including conventional RT, brachytherapy, radiosurgery, and concurrent chemoradiation, are frequently used following surgical salvage, but there are limited data as to their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Serious surgical complications include meningitis (the most common cause of perioperative mortality), osteoradionecrosis, necrosis of the free flap, and aspiration pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Other commonly seen complications include middle ear effusion, hypernasality, nasal regurgitation, cerebrospinal rhinorrhea, ectropion, temporary and permanent infra-orbital numbness, trismus, epiphora (watering eyes), impaired swallowing, and oro-palatal fistula.",
"   </p>",
"   <p>",
"    Salvage surgery for locally recurrent head and neck cancers is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reirradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for long-term survival with reirradiation, with or without induction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemotherapy, has been suggested by case series and phase II studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/6,18-32\">",
"     6,18-32",
"    </a>",
"    ]. However, reirradiation poses a therapeutic challenge since the dose that can be delivered safely is limited by previous RT treatments and the tolerance of normal tissues. Extent of local recurrence and adequate reirradiation dose impact the success of salvage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/19\">",
"     19",
"    </a>",
"    ]. Significant acute and late toxicities must be expected.",
"   </p>",
"   <p>",
"    Various techniques of reirradiation, individually and combined, have been investigated in this setting.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Three-dimensional conformal RT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/21,33\">",
"       21,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intensity modulated RT (IMRT) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intracavitary and interstitial brachytherapy, including implantation of radioactive gold grains [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/21-23,28-30\">",
"       21-23,28-30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stereotactic radiosurgery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/23,29\">",
"       23,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fractionated stereotactic radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/24,25,28\">",
"       24,25,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Proton beam therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of therapeutic approach depends upon local expertise and technical considerations, such as location and extent of recurrent disease. Reirradiation has also been combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based induction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemotherapy in small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Grade 3 to 4 late toxicities occur in at least 5 to 20 percent in some series and consist of temporal lobe necrosis, cranial nerve palsies, hearing loss, endocrine abnormalities, palatal fibrosis, trismus, chronic pain, and osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reirradiation for locally recurrent head and neck cancers is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"     \"Reirradiation for locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is a highly chemosensitive tumor, with response rates as high as 80 percent with some",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens. Thus, systemic chemotherapy is often used for patients with recurrent or metastatic disease, even though it has not been directly compared with supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Conventional chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of chemotherapy agents have demonstrated antitumor activity in patients with advanced or metastatic nasopharyngeal carcinoma; these include the platinum compounds (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ), 5-fluorouracil (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , taxanes (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , anthracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. Higher response rates have been observed when these agents are used in combinations, generally including a platinum compound. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials that have defined the optimal regimen. The most extensive data come from a retrospective, single institution study that included 822 patients treated between 1999 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients were treated with one of five regimens (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-fluorouracil, cisplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , cisplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , cisplatin plus 5-fluorouracil plus paclitaxel, or cisplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    plus 5-fluorouracil). Response rates (partial plus complete) with each of these regimens varied between 60 and 74 percent. There were no statistically significant differences in progression-free survival (median 5.0 to 6.6 months) or overall survival (median 19 to 21 months and three-year survival rates 19 to 21.5 months). Severe toxicity, particularly myelosuppression, was more severe with the cisplatin, paclitaxel, plus 5-fluorouracil regimen.",
"   </p>",
"   <p>",
"    The pre- and post-treatment plasma levels of EBV DNA may be a useful prognostic marker. In a study of 127 patients with metastatic or recurrent nasopharyngeal carcinoma treated with palliative chemotherapy, both a low pretreatment EBV DNA level and a fall in EBV DNA to undetectable levels following chemotherapy were associated with improved progression-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/45\">",
"     45",
"    </a>",
"    ]. Similarly, a worse prognosis was associated with an elevated level of EBV DNA in the previously cited observational series of patients treated with various",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    combination regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second-line chemotherapy may be considered for patients with a good performance status who become refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens, although response rates are lower than with first-line therapy. A small number of small studies have reported outcomes of treatment administered to patients who relapse after cisplatin-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/35-38,46-48\">",
"     35-38,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical studies provide a rationale for targeting epidermal growth factor receptor (EGFR)-mediated signaling as well as genes involved with tumor hypoxia, such as hypoxia-inducible factor (HIF), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), and c-KIT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Agents studied include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/50\">",
"     50",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/51\">",
"     51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/53\">",
"     53",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/54\">",
"     54",
"    </a>",
"    ]. Currently available data with these agents does not define a role for these agents in patients with nasopharyngeal carcinoma outside of a clinical trial setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) is present in virtually all poorly differentiated and undifferentiated nonkeratinizing nasopharyngeal carcinoma (WHO type II and III). Consequently, the viral antigens expressed by the tumor cells are attractive targets for immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two approaches are being investigated: adoptive immunotherapy, which bypasses antigen presentation and directly activates effector cells, and active immunotherapy, using EBV vaccination, which stimulates tumor antigen recognition by the host immune system. These strategies are investigational at present, although they show promise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adoptive immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adoptive transfer of cytotoxic T cells (CTLs) specific for EBV antigens has proved highly successful as prophylaxis for and treatment of EBV-associated lymphoproliferative disease (PTLD) arising in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/57\">",
"     57",
"    </a>",
"    ]. These highly immunogenic lymphomas in immunocompromised hosts, which serve as a model of virus-targeted immunotherapy for EBV-associated tumors, express all latent EBV antigens (latency type III). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\", section on 'Adoptive immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, in nasopharyngeal carcinoma and Hodgkin lymphoma, only a restricted set of less immunogenic viral antigens (latency type II), namely EBNA1 and latent membrane protein (LMP) 1 and 2, are expressed. EBNA1 is regularly expressed in nasopharyngeal carcinoma but is a dominant target for CD4+ T cells. Expression of LMP1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LMP2 is detectable in at least 50 percent of nasopharyngeal carcinoma tumors. LMP1 and LMP2 are both targets for CD8+ CTLs, but since responses detected in healthy virus carriers indicate that LMP1 is poorly immunogenic, the most likely target antigen for a CD8+ CTL based therapy is LMP2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first pilot study to treat nasopharyngeal carcinoma using adoptive T cell therapy was reported in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/61\">",
"     61",
"    </a>",
"    ]. Autologous EBV-transformed B-lymphoblastoid cell line (LCL) reactivated T cells were generated in vitro and used to treat four advanced cases of nasopharyngeal carcinoma. No adverse events occurred, and infusion of CTL was associated with a reduction of plasma EBV load. However, tumor responses were not seen in this pilot study.",
"   </p>",
"   <p>",
"    The use of autologous EBV-specific CTL for nasopharyngeal carcinoma has since been reported in two clinical trials, each with ten patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Both studies demonstrated that autologous EBV-specific CTL is safe, induces LMP2 specific immune response, and is associated with objective responses and control of disease in advanced nasopharyngeal carcinoma. Interestingly, in one patient with relapsed nasopharyngeal carcinoma, the adoptive transfer of an allogeneic EBV-specific CTL resulted in temporary stabilization of disease with local tumor biopsy showing an increase in tumor infiltrating CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     EBV vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine strategies include dendritic cells vaccination and viral vectors-introduced peptides. Dendritic cells, which are professional antigen-presenting cells that are critical in the activation of naive CD4+ and CD8+ T cells, are generated and maturated ex vivo, pulsed with tumor antigens, and administered to the patient. The second strategy is a replication-incompetent adenoviral vaccine that encodes multiple HLA class I-restricted CTL epitopes from LMP1 and LMP2.",
"   </p>",
"   <p>",
"    A vaccine of dendritic cells pulsed with peptides derived from LMP2 has been evaluated in 16 nasopharyngeal carcinoma patients with local recurrence or distant metastasis after conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/65\">",
"     65",
"    </a>",
"    ]. Peptide specific T cell responses were elicited or boosted in nine patients, and partial tumor reduction was observed in two patients. Currently, a therapeutic EBV vaccination trial is ongoing in the United Kingdom and Hong Kong using a modified vaccinia virus expressing an EBNA1-LMP2 fusion protein to elicit CD4+ and CD8+ T cells against the two EBV proteins expressed in nasopharyngeal carcinoma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Meanwhile, an LMP-based polyepitope vaccine has also been developed for EBV-associated Hodgkins disease and nasopharyngeal carcinoma, and is being tested in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16280/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. It appears that it is feasible to boost EBV-specific immune response in nasopharyngeal carcinoma patients and further investigations exploring EBV as a target for immunotherapy are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged survival with treatment of recurrent and metastatic nasopharyngeal carcinoma is an achievable goal for a subset of carefully selected patients. Although palliative chemotherapy has not been directly compared to supportive care alone, metastatic nasopharyngeal carcinoma has demonstrated high chemosensitivity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For appropriately selected patients with small local recurrences (recurrent stage T1 and T2 (",
"      <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"       table 1",
"      </a>",
"      )), we suggest an aggressive approach, using either surgical salvage or reirradiation with or without concurrent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These treatments are associated with significant serious toxicities, but may result in long-term survival. The decision between surgery or reirradiation is individually tailored, taking into consideration location and extent of the recurrent tumor and previous therapies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Locoregional recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with metastatic nasopharyngeal carcinoma, we suggest palliative combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Chemotherapy has a high response rate and appears likely to improve survival, but has important toxicities. A",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimen is favored, but other regimens are active. The superiority of any one combination has not been demonstrated in randomized trials. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognostic factors, such as performance status, disease-free interval, and site of metastatic disease, may be useful when selecting a palliative chemotherapy regimen and choosing between single agent and combination chemotherapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who become refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based therapy, second line chemotherapy or clinical trials investigating molecularly targeted therapy or immunotherapy approaches may provide treatment options. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/1\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Staging Manual, 7th, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes, L, Eveson, JW, Reichart, P, Sidransky, D (Eds), IARC Press, Lyon 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/4\">",
"      Lee AW, Foo W, Law SC, et al. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys 1999; 44:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/5\">",
"      Chua DT, Sham JS, Hung KN, et al. Predictive factors of tumor control and survival after radiosurgery for local failures of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/6\">",
"      Teo PM, Kwan WH, Chan AT, et al. How successful is high-dose (&gt; or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998; 40:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/7\">",
"      Smee RI, Meagher NS, Broadley K, et al. Recurrent nasopharyngeal carcinoma: current management approaches. Am J Clin Oncol 2010; 33:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/8\">",
"      Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/9\">",
"      Lee AW, Law SC, Foo W, et al. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys 1993; 26:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/10\">",
"      Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am 2008; 22:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/11\">",
"      Chen MY, Wen WP, Guo X, et al. Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope 2009; 119:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/12\">",
"      Fee WE Jr, Moir MS, Choi EC, Goffinet D. Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2- to 17-year follow-up. Arch Otolaryngol Head Neck Surg 2002; 128:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/13\">",
"      Hsu MM, Hong RL, Ting LL, et al. Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site: experience with 60 cases. Arch Otolaryngol Head Neck Surg 2001; 127:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/14\">",
"      Chang KP, Hao SP, Tsang NM, Ueng SH. Salvage surgery for locally recurrent nasopharyngeal carcinoma-A 10-year experience. Otolaryngol Head Neck Surg 2004; 131:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/15\">",
"      Yu KH, Leung SF, Tung SY, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005; 27:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/16\">",
"      To EW, Lai EC, Cheng JH, et al. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 31 patients and prognostic factors. Laryngoscope 2002; 112:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/17\">",
"      Hao SP, Tsang NM, Chang KP, et al. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors. Acta Otolaryngol 2008; 128:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/18\">",
"      Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol 2005; 28:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/19\">",
"      Lee AW, Foo W, Law SC, et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 1997; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/20\">",
"      Poon D, Yap SP, Wong ZW, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/21\">",
"      Zheng XK, Chen LH, Chen YQ, Deng XG. Three-dimensional conformal radiotherapy versus intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 60:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/22\">",
"      Leung TW, Tung SY, Wong VY, et al. Nasopharyngeal intracavitary brachytherapy: the controversy of T2b disease. Cancer 2005; 104:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/23\">",
"      Low JS, Chua ET, Gao F, Wee JT. Stereotactic radiosurgery plus intracavitary irradiation in the salvage of nasopharyngeal carcinoma. Head Neck 2006; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/24\">",
"      Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/25\">",
"      Orecchia R, Redda MG, Ragona R, et al. Results of hypofractionated stereotactic re-irradiation on 13 locally recurrent nasopharyngeal carcinomas. Radiother Oncol 1999; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/26\">",
"      Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy--dose-volume histogram analysis. Radiology 1999; 213:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/27\">",
"      Pai PC, Chuang CC, Wei KC, et al. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 2002; 24:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/28\">",
"      Yau TK, Sze WM, Lee WM, et al. Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma. Head Neck 2004; 26:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/29\">",
"      Chua DT, Wei WI, Sham JS, et al. Stereotactic radiosurgery versus gold grain implantation in salvaging local failures of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/30\">",
"      Koutcher L, Lee N, Zelefsky M, et al. Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/31\">",
"      Lu TX, Mai WY, Teh BS, et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 58:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/32\">",
"      Chua DT, Sham JS, Leung LH, Au GK. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol 2005; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/33\">",
"      Zheng XK, Ma J, Chen LH, et al. Dosimetric and clinical results of three-dimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2005; 75:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/34\">",
"      Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012; 138:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/35\">",
"      Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003; 39:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/36\">",
"      Ciuleanu E, Irimie A, Ciuleanu TE, et al. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. J BUON 2008; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/37\">",
"      Poon D, Chowbay B, Cheung YB, et al. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer 2005; 103:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/38\">",
"      Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 2011; 22:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/39\">",
"      Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol 1998; 9:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/40\">",
"      Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/41\">",
"      Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/42\">",
"      Chua DT, Kwong DL, Sham JS, et al. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer 2000; 36:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/43\">",
"      Dugan M, Choy D, Ngai A, et al. Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. J Clin Oncol 1993; 11:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/44\">",
"      Airoldi M, Gabriele AM, Garzaro M, et al. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol 2009; 92:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/45\">",
"      An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011; 117:3750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/46\">",
"      Wang CC, Chang JY, Liu TW, et al. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck 2006; 28:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/47\">",
"      Chen C, Wang FH, Wang ZQ, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/48\">",
"      Yau TK, Shum T, Lee AW, et al. A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma. Oral Oncol 2012; 48:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/49\">",
"      Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer 2005; 92:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/50\">",
"      Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23:3568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/51\">",
"      Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/52\">",
"      Lim WT, Ng QS, Ivy P, et al. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 2011; 17:5481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/53\">",
"      Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008; 30:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/54\">",
"      You B, Le Tourneau C, Chen EX, et al. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol 2012; 35:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/55\">",
"      Masmoudi A, Toumi N, Khanfir A, et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat Rev 2007; 33:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/56\">",
"      Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/57\">",
"      Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/58\">",
"      Whitney BM, Chan AT, Rickinson AB, et al. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 2002; 67:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/59\">",
"      Lee SP, Chan AT, Cheung ST, et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000; 165:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/60\">",
"      Bell AI, Groves K, Kelly GL, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 2006; 87:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/61\">",
"      Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 2001; 94:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/62\">",
"      Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 2005; 105:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/63\">",
"      Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23:8942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/64\">",
"      Comoli P, De Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/65\">",
"      Lin CL, Lo WF, Lee TH, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62:6952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/66\">",
"      Taylor GS, Haigh TA, Gudgeon NH, et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 2004; 78:768.",
"     </a>",
"    </li>",
"    <li>",
"     Hui EP, Ma BB, Chan SL, et al. Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC) (abstract #3052). J Clin Oncol 26:2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/68\">",
"      Duraiswamy J, Sherritt M, Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16280/abstract/69\">",
"      Duraiswamy J, Bharadwaj M, Tellam J, et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 2004; 64:1483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3381 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16280=[""].join("\n");
var outline_f15_57_16280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LOCOREGIONAL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Salvage surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reirradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Conventional chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adoptive immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - EBV vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/8/34957\" title=\"table 1\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=related_link\">",
"      Reirradiation for locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_57_16281="Corticosteroid therapy in septic shock";
var content_f15_57_16281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Corticosteroid therapy in septic shock",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16281/contributors\">",
"     David A Kaufman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Jordi Mancebo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16281/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/57/16281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in the role of glucocorticoids in the pathophysiology of critical illness has existed since the early part of the 20th century, when investigators observed that the adrenal glands are crucial to survival under conditions of physiologic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The subsequent development of cortisone for clinical use was followed by clinical studies exploring the potential therapeutic role of corticosteroids in the treatment of severe infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following issues are discussed in this topic review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effects of critical illness on the hypothalamic-pituitary-adrenal axis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of critical illness'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Methods of evaluating adrenal reserve (random cortisol levels, synthetic adrenocorticotropic hormone [ACTH] stimulation tests, free cortisol levels) and the impact of each on prognosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Assessing adrenal reserve'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The concept of relative adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Relative adrenal insufficiency'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Clinical evidence from trials evaluating the effect of corticosteroid therapy in patients with septic shock, plus practical aspects of corticosteroid administration. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Corticosteroid therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Recommendations regarding the role of corticosteroid therapy in patients with septic shock. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Summary and recommendations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of the management of severe sepsis and septic shock are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF CRITICAL ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus continuously integrates stimuli and secretes corticotropin releasing hormone (CRH) whenever homeostasis is threatened. CRH stimulates the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, which induces cortisol secretion from the adrenal glands. Cortisol is the effector molecule of the hypothalamic-pituitary-adrenal (HPA) axis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Activation of the HPA axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal serum cortisol levels range between 5 and 24",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    with significant variability depending upon the time of day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/8\">",
"     8",
"    </a>",
"    ]. The HPA axis is activated and diurnal variation is lost during physiological stress (eg, major surgery, hypotension, severe infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Serum cortisol increases as a result, reaching levels as high as 40 to 50",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef66966 \" href=\"UTD.htm?13/41/13982\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/9,11-15\">",
"     9,11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to activation of the HPA axis by physiological stress, cortisol metabolism and function may be considerably altered by other aspects of critical illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal dysfunction may prolong the half-life of circulating cortisol.",
"     </li>",
"     <li>",
"      Plasma concentrations of both cortisol binding globulin (CBG) and albumin, which bind &gt;90 percent of circulating cortisol under normal circumstances, are frequently diminished. This results in an increase in the free cortisol, which is believed to be the physiologically active form of the hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/11,16,17\">",
"       11,16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory cytokines may increase glucocorticoid receptor affinity, disable glucocorticoid inactivation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase the peripheral conversion of precursors to cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/11,18,19\">",
"       11,18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impairment of the HPA axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are circumstances in which cortisol availability cannot be increased sufficiently to meet demand. As an example, drugs like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    may impair cortisol synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/11,20,21\">",
"     11,20,21",
"    </a>",
"    ]. An observational study of 62 patients found that the use of etomidate for intubation was associated with increased likelihood of having a poor response (&le;9",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    to ACTH stimulation 24 hours later (odds ratio 12, 95% CI 3-50) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical importance of this observation is uncertain. While some evidence suggests that a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is associated with worse outcomes in patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/23\">",
"     23",
"    </a>",
"    ], a randomized trial that compared etomidate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    for rapid sequence induction found that etomidate was NOT associated with worse clinical outcomes despite an increased incidence of adrenocortical hyporesponsiveness to synthetic adrenocorticotropic hormone (ACTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/24\">",
"     24",
"    </a>",
"    ]. The clinical implications of these findings are uncertain because both studies measured plasma cortisol using an immunoassay, which correlates poorly with the reference standard (liquid chromatography with mass spectroscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Head injury, central nervous system depressants, pituitary infarction, adrenal hemorrhage, infections, malignancy, and previous corticosteroid therapy can also impair the HPA axis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/11\">",
"     11",
"    </a>",
"    ]. Sometimes an etiology cannot be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSESSING ADRENAL RESERVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Random serum cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum cortisol levels vary widely in patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/14,26-31\">",
"     14,26-31",
"    </a>",
"    ]. This observation led multiple investigators to try to determine whether serum cortisol is predictive of mortality in patients with septic shock. Numerous studies found increased mortality associated with both low serum cortisol levels and high serum cortisol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. Other studies were unable to find a relationship between cortisol levels and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/27,29,38\">",
"     27,29,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ACTH stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adrenocorticotropic hormone (ACTH) stimulation test requires that a baseline serum cortisol be drawn and then synthetic ACTH (cosyntropin) administered intravenously. Serum cortisol levels are drawn 30 and 60 minutes later.",
"   </p>",
"   <p>",
"    There are two types of ACTH stimulation tests. A high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    involves the administration of 250 mcg of synthetic ACTH. In contrast, a low-dose ACTH stimulation test involves the administration of only 1 mcg of synthetic ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     High-dose ACTH test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using a high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    have yielded variable results in septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/27,30,38-40\">",
"     27,30,38-40",
"    </a>",
"    ]. A prospective cohort study performed high-dose ACTH stimulation tests on 189 patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/40\">",
"     40",
"    </a>",
"    ]. The results correlated with 28-day mortality: a baseline serum cortisol level &gt;34",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    and a maximum increase in cortisol of &le;9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    were identified as risk factors for death. Three prognostic groups were proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good prognosis (26 percent mortality): Baseline plasma cortisol &le;34",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      and a cortisol increase &gt;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      in response to cosyntropin.",
"     </li>",
"     <li>",
"      Poor prognosis (82 percent mortality): Baseline plasma cortisol &gt;34",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      and a cortisol increase &le;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      in response to cosyntropin.",
"     </li>",
"     <li>",
"      Intermediate prognosis (67 percent mortality): Baseline plasma cortisol &gt;34",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      and a cortisol increase &gt;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      in response to cosyntropin, or baseline plasma cortisol &le;34",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      and a cortisol increase &le;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      in response to cosyntropin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results from this study are supported by a more recent and larger retrospective cohort study, in which 477 patients with severe sepsis or septic shock underwent high-dose ACTH testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/41\">",
"     41",
"    </a>",
"    ]. Nonsurvivors had a higher baseline cortisol level (30 versus 24",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    and a smaller cortisol increase (6 versus 11",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    than survivors. Patients with either a baseline cortisol level &lt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or a cortisol increase &le;9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    had a higher mortality, longer duration of shock, or shorter survival time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Low-dose ACTH test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators believe that 250 mcg of cosyntropin is supraphysiologic and stimulates adrenal secretion of cortisol even when adrenal dysfunction exists, noting that even patients with impaired adrenal reserve can mount an apparently normal adrenal response to such a high dose of cosyntropin. Use of low-dose (1 mcg) cosyntropin has been proposed as an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Low-dose ACTH stimulation test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two investigations have compared a low-dose (1 mcg)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    to a high-dose (250 mcg) ACTH stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first study was a prospective cohort study of 59 patients with septic shock who were sequentially administered 1 mcg and 250 mcg of cosyntropin intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/43\">",
"     43",
"    </a>",
"    ]. All of the patients then received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    100 mg intravenously every eight hours. Patients were designated as steroid responsive if they were able to maintain a mean arterial blood pressure &gt;65 mmHg without norepinephrine infusion within 24 hours after starting hydrocortisone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenal insufficiency (defined as post-cosyntropin serum cortisol of &lt;18",
"      <span class=\"nowrap\">",
"       mcg/dL)",
"      </span>",
"      was detected in more patients by low-dose ACTH testing than high-dose ACTH testing (22 versus 8 percent).",
"     </li>",
"     <li>",
"      54 percent of steroid responders had a diagnostic low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      , while 22 percent had a diagnostic high-dose ACTH stimulation test. This suggests that adrenal insufficiency detected by low-dose ACTH stimulation was superior to that detected by high-dose ACTH stimulation in predicting hemodynamic responsiveness to corticosteroids.",
"     </li>",
"     <li>",
"      Retrospective evaluation demonstrated that a random serum cortisol level &lt;25",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      was the most accurate diagnostic threshold, predicting steroid responsiveness in 96 percent of the subjects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second study was similar, administering low-dose (1 mcg) and high-dose (250 mcg) cosyntropin consecutively to 46 patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/44\">",
"     44",
"    </a>",
"    ]. Serum cortisol levels were measured at baseline and after each stimulation test. A positive response to ACTH stimulation was defined as a serum cortisol increase &gt;9",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    Patients who responded to low-dose and high-dose ACTH were more likely to survive than those who did not respond to either dose. In addition, a response only to high-dose ACTH stimulation was associated with lower survival than a response to both low-dose and high-dose ACTH stimulation, suggesting that low-dose ACTH stimulation identified a subgroup of patients with inadequate adrenal reserve that would have been missed by high-dose ACTH stimulation alone.",
"   </p>",
"   <p>",
"    Larger studies are needed before the significance of the findings from these two investigations can be fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTH stimulation tests may be unreliable in critically ill patients for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some critically ill individuals have spontaneous increases in their serum cortisol of &ge;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      WITHOUT cosyntropin stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/45\">",
"       45",
"      </a>",
"      ]. Thus, this threshold may not be clinically helpful.",
"     </li>",
"     <li>",
"      ACTH stimulation tests may give inconsistent results in the same individuals if performed on more than one occasion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/27,46\">",
"       27,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most clinical laboratories use immunoassays to measure the total cortisol because the reference standard, liquid chromatography-tandem mass spectrometry",
"      <span class=\"nowrap\">",
"       (LC-MS/MS),",
"      </span>",
"      is a time- and labor-intensive assay that is not available in most centers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/47\">",
"       47",
"      </a>",
"      ]. However, immunoassays appear to correlate poorly with",
"      <span class=\"nowrap\">",
"       LC-MS/MS",
"      </span>",
"      during septic shock. This was illustrated by a study of 425 ACTH stimulation tests (850 cortisol samples) that found that approximately 27 percent of the samples were incorrectly classified by immunoassays [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Free cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In critically ill patients, loss of cortisol binding globulin (CBG) results in decreased protein-bound cortisol and increased free cortisol. Therefore, for any given amount of serum total cortisol, there is a shift from inactive protein-bound cortisol to physiologically active free cortisol. This suggests that standard assays for plasma cortisol (which measure total plasma cortisol) underestimate HPA axis activity. It has been proposed that free cortisol more accurately reflects HPA axis activation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a study comparing total serum cortisol and free serum cortisol levels in 33 healthy volunteers to those in 60 critically ill patients (18 had sepsis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/49\">",
"     49",
"    </a>",
"    ]. The critically ill patients had total serum cortisol concentrations that were two to three times higher and free cortisol levels that were 7 to 10 times higher than healthy volunteers. Although the total serum cortisol appeared lower in critically ill patients with hypoalbuminemia (albumin &le;2.5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    than in critically ill patients with preserved albumin concentrations, the free cortisol levels were similar.",
"   </p>",
"   <p>",
"    The study has two major limitations. First, the critically ill patients did not include any patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/50\">",
"     50",
"    </a>",
"    ]. Second, the degree of hemodynamic instability at the time of plasma cortisol sampling was not reported. Thus, it is impossible to correlate the cortisol level with severity of illness or physiologic status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/51\">",
"     51",
"    </a>",
"    ]. The applicability of the study to routine clinical practice is uncertain because the free cortisol assay is not available at most clinical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another investigation, 74 patients had their total and free cortisol levels measured before and after the administration of 250 mcg of cosyntropin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-stimulation free cortisol levels were higher in patients with septic shock (186",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      than sepsis (29",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      or healthy controls (13",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Pre-stimulation free cortisol levels reflected the severity of illness more closely than total cortisol levels.",
"     </li>",
"     <li>",
"      The calculated free cortisol level (based on direct measurements of total cortisol and the CBG concentration) correlated well with the direct measurement of free cortisol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the free cortisol level provides useful prognostic information in critically ill patients has not been formally investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RELATIVE ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol is necessary to survive critical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. But, how much is enough?",
"   </p>",
"   <p>",
"    Absolute adrenal insufficiency is rare among critically ill patients, with an incidence estimated to be &le;3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the following observations argue that suboptimal cortisol production may be common and associated with worse outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A maximum increase of serum cortisol &le;9",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      following intravenous synthetic adrenocorticotropic hormone (ACTH) stimulation is associated with increased mortality from septic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/40,44\">",
"       40,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Baseline and post-ACTH serum cortisol &lt;23.7",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      predict responsiveness to exogenous steroids in septic shock, where responsiveness is defined by the ability to maintain a mean arterial blood pressure &gt;65 mmHg without norepinephrine infusion within 24 hours after starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suboptimal cortisol production during septic shock has been termed \"functional\" or \"relative\" adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/11\">",
"     11",
"    </a>",
"    ]. This condition has also been called &ldquo;critical illness-related corticosteroid insufficiency (CIRCI)&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/55\">",
"     55",
"    </a>",
"    ]. There is no consensus about the diagnostic criteria or indications for treatment of this entity. In addition, there exists considerable disagreement over what cortisol level is \"normal\" or \"appropriate\" in septic shock, what constitutes an adequate response to ACTH, and what dose of synthetic ACTH should be used for stimulation testing.",
"   </p>",
"   <p>",
"    The question of how much cortisol is enough for a critically ill patient is confounded by the possibility that glucocorticoid resistance exists at the target-tissue level. Few data support the notion that genetic or acquired glucocorticoid receptor abnormalities affect critically ill patients. Assays of the cellular activity of cortisol, cortisol-glucocorticoid-receptor binding, and glucocorticoid-receptor transcription activity are limited to experimental investigations and their clinical relevance is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/56\">",
"     56",
"    </a>",
"    ]. The mechanisms of glucocorticoid resistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link&amp;anchor=H4#H4\">",
"     \"Glucocorticoid-resistant asthma\", section on 'Mechanisms of glucocorticoid resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using an overnight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test as the reference standard, a prospective cohort study found that patients with septic shock who had a baseline total cortisol level &lt;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or a change in total cortisol &lt;9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    after high-dose ACTH stimulation, were likely to have adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/57\">",
"     57",
"    </a>",
"    ]. Conversely, patients with septic shock who had a baseline total cortisol level &ge;44",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or a change in total cortisol &ge;16.8",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    were unlikely to have adrenal insufficiency. The generalizability of these results has been questioned because the frequency of absolute adrenal insufficiency in this study was nearly four times that previously reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, the values were not used to guide therapeutic decision making and, therefore, their impact on clinical outcome is unknown.",
"   </p>",
"   <p>",
"    We believe that it is uncertain whether \"relative adrenal insufficiency\" or a synonymous condition is a true diagnostic entity, since a clear definition is lacking and the cortisol assays that are available at most clinical laboratories are unreliable in the critically ill patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CORTICOSTEROID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in the possible therapeutic role of corticosteroids in severe infections has existed for at least 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/4-7,59,60\">",
"     4-7,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1980s, three randomized, double-blind, placebo-controlled studies were published [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. None of the trials found a mortality benefit and only one trial noted decreased duration to shock resolution associated with the administration of corticosteroids. All of the trials administered high-dose corticosteroids for a short duration and used early endpoints.",
"   </p>",
"   <p>",
"    In the 1990s, interest in corticosteroids as a therapy in septic shock was renewed, this time using smaller, more physiological doses for longer duration. Three small trials (approximately 40 patients each) compared corticosteroid administration to placebo in patients with septic shock and found decreased duration of shock associated with corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. These trials prompted larger randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     French trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter, double-blind trial conducted in France, 300 patients were randomly assigned to receive placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (50 mg intravenously every six hours) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (50 mcg enterally once a day) within eight hours of the onset of septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/67\">",
"     67",
"    </a>",
"    ]. Treatment continued for seven days. Based upon a high-dose (250 mcg)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    , the patients were classified as having adequate adrenal reserve (maximum increase in serum cortisol of &gt;9",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    or inadequate adrenal reserve (maximum cortisol increase of &le;9",
"    <span class=\"nowrap\">",
"     mcg/dL):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among",
"      all patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      administration decreased 28-day mortality (55 versus 61 percent)",
"     </li>",
"     <li>",
"      Among patients defined as having inadequate adrenal reserve,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      administration decreased 28-day mortality (53 versus 63 percent), ICU mortality (58 versus 70 percent), and hospital mortality (61 versus 72 percent), as well as more vasopressor withdrawal (57 versus 40 percent)",
"     </li>",
"     <li>",
"      Among patients defined as having adequate adrenal reserve, there was no difference in mortality or vasopressor withdrawal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trial was criticized for its high placebo-group mortality and the statistical methods used to describe outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between corticosteroid therapy and improved mortality was supported by two subsequent meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. However, no significant benefit was noted in a large randomized trial (CORTICUS) published after the meta-analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     CORTICUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Corticosteroid Therapy of Septic Shock (CORTICUS) trial was a multicenter, double-blind trial that randomly assigned 499 patients with septic shock to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (50 mg) or placebo intravenously every six hours for five days, followed by a tapering regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/73\">",
"     73",
"    </a>",
"    ]. Based upon a high-dose (250 mcg)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    , the patients were classified as having inadequate adrenal reserve (maximum cortisol increase of &le;9",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    or adequate adrenal reserve (maximum increase in serum cortisol of &gt;9",
"    <span class=\"nowrap\">",
"     mcg/dL).",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    administration did not improve 28-day mortality (35 versus 32 percent in the placebo group). This was also true in the two pre-defined subgroups &ndash; patients with inadequate adrenal reserve and patients with adequate adrenal reserve. The hydrocortisone group had faster reversal of shock among all patients (3.3 versus 5.8 days in the placebo group) and increased incidence of new infection that did not reach statistical significance (odds ratio 1.27, 95% CI 0.96-1.68). The trial was criticized for the lower than expected placebo-group mortality (32 percent versus the anticipated 50 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Comparison of French trial and CORTICUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;These randomized trials have important differences that may, at least in part, explain their conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The French trial enrolled patients within eight hours after the onset of shock and included patients with a greater severity of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/67\">",
"       67",
"      </a>",
"      ]. The mean Simplified Acute Physiology Score II (SAPS II) was 55.5 and septic shock was defined as a systolic blood pressure &lt;90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration.",
"     </li>",
"     <li>",
"      The CORTICUS trial enrolled patients within 72 hours of the onset of shock and included patients with a lower severity of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/73\">",
"       73",
"      </a>",
"      ]. The mean SAPS II was 49 and septic shock was defined as a systolic blood pressure &lt;90 mmHg despite adequate fluid resuscitation, or the need for vasopressor administration for more than one hour.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences imply that corticosteroid therapy is most likely to benefit patients with severe septic shock. This was supported by two meta-analyses that looked at the effects of long courses of low-dose steroids (&le;300 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or an equivalent for &ge;5 days) in patients with septic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 12 randomized and quasi-randomized trials (1228 patients) found that corticosteroid treatment decreased mortality compared to placebo or supportive care (38 versus 44 percent, relative risk 0.84, 95% CI 0.72-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/74\">",
"       74",
"      </a>",
"      ]. A meta-regression analysis found a significant association between the severity of illness and the effect of corticosteroids on mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, a meta-analysis of 12 randomized trials (1171 patients) found that corticosteroid treatment decreased mortality compared to placebo or supportive care (38 versus 44 percent, odds ratio 0.64, 95% CI 0.45-0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/76\">",
"       76",
"      </a>",
"      ]. A meta-regression analysis found that more severely ill patients were more likely to benefit from corticosteroid therapy and that corticosteroid therapy was more harmful in less severely ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both meta-analyses detected possible publication bias and the latter meta-analyses had a moderate amount of heterogeneity, limiting our confidence in the estimate of the effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H128688839\">",
"    <span class=\"h3\">",
"     Surviving sepsis campaign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Surviving Sepsis Campaign provides a large observational database of 17,847 patients who required vasopressor therapy despite fluid resuscitation and met eligibility criteria for low-dose systemic corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    50 mg intravenously every six hours or 100 mg every eight hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/78\">",
"     78",
"    </a>",
"    ]. A total of 8992 patients (50 percent) received low-dose corticosteroids, and the hospital mortality was higher in those receiving corticosteroids than those without (41 versus 35 percent, respectively) with an adjusted odds ratio of 1.18 (95% CI 1.09-1.213). No significant difference in mortality was noted in those who received corticosteroids before 8 hours or between 8 and 24 hours. Despite the large size of this study, the observational nature potentially limits the conclusions. It is important to await the results of two pending randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conclusions can be based upon the available evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although some studies suggest that corticosteroid therapy is most likely to be beneficial to patients who have severe septic shock (which we define as a systolic blood pressure &lt;90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration), especially if begun within eight hours of the onset of shock, the data from ongoing clinical trials are needed to confirm that benefit. &nbsp;",
"     </li>",
"     <li>",
"      There are no high or moderate quality data to suggest that corticosteroid therapy is beneficial to patients with less severe septic shock.",
"     </li>",
"     <li>",
"      Laboratory assays of plasma cortisol concentration may be unreliable in critically ill patients and fail to identify patients who are more likely to benefit from corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High-dose ACTH test'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    is a pharmacologic form of cortisol. Compared to hydrocortisone, other pharmacologic corticosteroids bind cortisol-binding globulin (CBG) poorly, resulting in more free, physiologically active corticosteroid and greater potency at any given dose. The different preparations vary widely in anti-inflammatory and mineralocorticoid potency.",
"   </p>",
"   <p>",
"    Most studies evaluating the effect of corticosteroids in septic shock used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , although administration protocols and treatment durations varied. It is unknown whether the findings can be generalized to other synthetic corticosteroids. We typically administer 50 mg of hydrocortisone every six hours or 100 mg of hydrocortisone every eight hours.",
"   </p>",
"   <p>",
"    There is no consensus regarding the optimal administration protocol or treatment duration, because no study has compared fixed-duration regimens to clinically-guided regimens, or tapering to abrupt cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/79\">",
"     79",
"    </a>",
"    ]. However, in one clinical study, abrupt cessation was associated with rebound of hemodynamic abnormalities and increased inflammatory markers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one of the large randomized trials added",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    at a dose of 50 mcg per day for seven days, we do not typically add fludrocortisone because we believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    alone has sufficient mineralocorticoid effect and absorption of the enterally administered drug is questionable in situations of compromised splanchnic perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/67\">",
"     67",
"    </a>",
"    ]. Our decision to forego fludrocortisone is supported by a trial (the Corticosteroids and Intensive Insulin Therapy for Septic Shock [COIITSS] trial) that randomly assigned 509 patients with septic shock to receive either hydrocortisone plus fludrocortisone or hydrocortisone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16281/abstract/81\">",
"     81",
"    </a>",
"    ]. There was no difference in any of the clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically available tests that measure plasma cortisol are likely unreliable in critically ill patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Assessing adrenal reserve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-dose (250 mcg) synthetic adrenocorticotropic hormone (ACTH) stimulation may separate patients with septic shock into different prognostic groups. However, the unreliability of available plasma cortisol assays make the clinical usefulness of this test doubtful. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High-dose ACTH test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suboptimal cortisol production during septic shock has been termed \"functional\" adrenal insufficiency, \"relative\" adrenal insufficiency, or &ldquo;critical illness-related corticosteroid insufficiency (CIRCI)&rdquo;. Broadly accepted consensus about diagnostic criteria for this entity is lacking. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Relative adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although some studies suggest that corticosteroid therapy is most likely to be beneficial to patients who have severe septic shock (which we define as a systolic blood pressure &lt;90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration), especially if begun within eight hours of the onset of shock, the data from ongoing clinical trials are needed to confirm that benefit. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no high or moderate quality data to suggest that corticosteroid therapy is beneficial to patients with less severe septic shock. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classification of adrenal reserve as adequate or inadequate fails to identify patients who are more likely to benefit from corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical evidence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe septic shock (defined as a systolic blood pressure &lt;90 mmHg for more than one hour despite both adequate fluid resuscitation and vasopressor administration), we suggest initiation of intravenous corticosteroid therapy within eight hours after the onset of shock (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Response to ACTH testing should not be used to select patients for corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that corticosteroids be administered for five to seven days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A tapering course is optional; however, close observation of those patients whose steroid therapy is stopped without being tapered is warranted. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      NOT be added to the corticosteroid regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/1\">",
"      Scott WJ. THE INFLUENCE OF THE ADRENAL GLANDS ON RESISTANCE : II. THE TOXIC EFFECT OF KILLED BACTERIA IN ADRENALECTOMIZED RATS. J Exp Med 1924; 39:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/2\">",
"      Seyle, H. A syndrome produced by diverse nocuous agents. Nature 1936; 138:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/3\">",
"      HENCH PS, SLOCUMB CH, POLLEY HF, KENDAL EC. Effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases. J Am Med Assoc 1950; 144:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/4\">",
"      SPINK WW. ACTH and adrenocorticosteroids as therapeutic adjuncts in infectious diseases. N Engl J Med 1957; 257:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/5\">",
"      WAGNER HN Jr, BENNETT IL Jr, LASAGNA L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956; 98:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/6\">",
"      KASS EH. Adrenocorticosteroids and the management of infectious diseases. AMA Arch Intern Med 1958; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/7\">",
"      Bennett, IL Jr, Finland, M, Hamburger, M. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963; 183:462.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart PM. The Adrenal Cortex. In: Williams Textbook of Endocrinology, Polonsky KS (Ed), Saunders, Philadelphia 2002. p.491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/9\">",
"      Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997; 337:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/10\">",
"      Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 2001; 163:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/11\">",
"      Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/12\">",
"      Newsome HH, Rose JC. The response of human adrenocorticotrophic hormone and growth hormone to surgical stress. J Clin Endocrinol Metab 1971; 33:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/13\">",
"      HUME DM, BELL CC, BARTTER F. Direct measurement of adrenal secretion during operative trauma and convalescence. Surgery 1962; 52:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/14\">",
"      Vadas P, Pruzanski W. Plasma cortisol levels in patients with septic shock. Crit Care Med 1991; 19:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/15\">",
"      Boonen E, Vervenne H, Meersseman P, et al. Reduced Cortisol Metabolism during Critical Illness. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/16\">",
"      Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001; 27:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/17\">",
"      Hammond GL, Smith CL, Paterson NA, Sibbald WJ. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990; 71:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/18\">",
"      Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001; 16:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/19\">",
"      Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84:2834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/20\">",
"      WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/21\">",
"      Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/22\">",
"      Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/23\">",
"      Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009; 35:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/24\">",
"      Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/25\">",
"      Kaufman D. Etomidate versus ketamine for sedation in acutely ill patients. Lancet 2009; 374:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/26\">",
"      MELBY JC, SPINK WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/27\">",
"      Bouachour G, Roy PM, Guiraud MP. The repetitive short corticotropin stimulation test in patients with septic shock. Ann Intern Med 1995; 123:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/28\">",
"      Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977; 186:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/29\">",
"      Schein RM, Sprung CL, Marcial E, et al. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/30\">",
"      Moran JL, Chapman MJ, O'Fathartaigh MS, et al. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/31\">",
"      Briegel J, Schelling G, Haller M, et al. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996; 22:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/32\">",
"      McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983; 1:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/33\">",
"      Jurney TH, Cockrell JL Jr, Lindberg JS, et al. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987; 92:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/34\">",
"      Span LF, Hermus AR, Bartelink AK, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992; 18:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/35\">",
"      Jarek MJ, Legare EJ, McDermott MT, et al. Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993; 21:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/36\">",
"      Drucker D, Shandling M. Variable adrenocortical function in acute medical illness. Crit Care Med 1985; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/37\">",
"      Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995; 23:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/38\">",
"      Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/39\">",
"      Bouachour G, Tirot P, Gouello JP, et al. Adrenocortical function during septic shock. Intensive Care Med 1995; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/40\">",
"      Annane D, S&eacute;bille V, Troch&eacute; G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/41\">",
"      Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007; 35:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/42\">",
"      Marik P, Zaloga G. Prognostic value of cortisol response in septic shock. JAMA 2000; 284:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/43\">",
"      Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/44\">",
"      Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. Crit Care Med 2005; 33:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/45\">",
"      Venkatesh B, Mortimer RH, Couchman B, Hall J. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study. Anaesth Intensive Care 2005; 33:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/46\">",
"      Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg 2005; 101:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/47\">",
"      Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 2009; 360:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/48\">",
"      Briegel J, Sprung CL, Annane D, et al. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/49\">",
"      Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/50\">",
"      Polderman KH, van Zanten A, Girbes AR. Free cortisol and critically ill patients. N Engl J Med 2004; 351:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/51\">",
"      Dubey A, Boujoukos AJ. Measurements of serum free cortisol in critically ill patients. Crit Care 2005; 9:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/52\">",
"      Khan T, Kupfer Y, Tessler S. Free cortisol and critically ill patients. N Engl J Med 2004; 351:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/53\">",
"      Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab 2006; 91:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/54\">",
"      Burry LD, Wax RS. Role of corticosteroids in septic shock. Ann Pharmacother 2004; 38:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/55\">",
"      Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/56\">",
"      Peeters RP, Hagendorf A, Vanhorebeek I, et al. Tissue mRNA expression of the glucocorticoid receptor and its splice variants in fatal critical illness. Clin Endocrinol (Oxf) 2009; 71:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/57\">",
"      Annane D, Maxime V, Ibrahim F, et al. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/58\">",
"      Meyer NJ, Hall JB. Relative adrenal insufficiency in the ICU: can we at least make the diagnosis? Am J Respir Crit Care Med 2006; 174:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/59\">",
"      Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/60\">",
"      Shine KI, Kuhn M, Young LS, Tillisch JH. Aspects of the management of shock. Ann Intern Med 1980; 93:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/61\">",
"      Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/62\">",
"      Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/63\">",
"      Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987; 317:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/64\">",
"      Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/65\">",
"      Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/66\">",
"      Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/67\">",
"      Annane D, S&eacute;bille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/68\">",
"      Beigel J, Eichacker P. Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency. ACP J Club 2003; 138:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/69\">",
"      Rubenfeld, GD. When survival is not the same as mortality. Critical Care Alert 2003; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/70\">",
"      Eisen LA. Epoetin alfa in critically ill patients. N Engl J Med 2007; 357:2516; author reply 2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/71\">",
"      Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004; :CD002243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/72\">",
"      Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/73\">",
"      Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/74\">",
"      Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/75\">",
"      Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/76\">",
"      Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/77\">",
"      Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/78\">",
"      Casserly B, Gerlach H, Phillips GS, et al. Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign. Intensive Care Med 2012; 38:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/79\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/80\">",
"      Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of \"low-dose\" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16281/abstract/81\">",
"      COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1654 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16281=[""].join("\n");
var outline_f15_57_16281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF CRITICAL ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Activation of the HPA axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impairment of the HPA axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSESSING ADRENAL RESERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Random serum cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACTH stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - High-dose ACTH test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Low-dose ACTH test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Free cortisol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RELATIVE ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CORTICOSTEROID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - French trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - CORTICUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Comparison of French trial and CORTICUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H128688839\">",
"      - Surviving sepsis campaign",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1654|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/41/13982\" title=\"figure 1\">",
"      Cortisol in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_57_16282="Overview of the risk factors, pathology, and clinical manifestations of lung cancer";
var content_f15_57_16282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16282/contributors\">",
"     David E Midthun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16282/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/57/16282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/57/16282/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/57/16282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cancer worldwide, with an estimated 1,600,000 new cases and 1,380,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, there will be an estimated 228,000 new cases of lung cancer and 159,500 deaths in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the absolute and relative frequency of lung cancer has risen dramatically. As an example, the age-adjusted death rate from lung cancer is similar to that of pancreatic cancer prior to 1930 for men (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032005.pdf\">",
"     Graph death rates",
"    </a>",
"    ) and prior to 1960 for women (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032006.pdf\">",
"     Graph death rates",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/3\">",
"     3",
"    </a>",
"    ]. Around 1953, lung cancer became the most common cause of cancer deaths in men, and in 1985, it became the leading cause of cancer deaths in women. Lung cancer deaths have begun to decline in both men and women, reflecting a decrease in smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link\">",
"     \"Women and lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term lung cancer, or bronchogenic carcinoma, refers to malignancies that originate in the airways or pulmonary parenchyma. Approximately 95 percent of all lung cancers are classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). This distinction is essential for staging, treatment, and prognosis. Other cell types comprise about 5 percent of malignancies arising in the lung.",
"   </p>",
"   <p>",
"    This discussion will present an overview of the risk factors, pathology, and clinical manifestations of NSCLC and SCLC. An overview of the initial evaluation, treatment, and prognosis of lung cancer is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of environmental and life-style factors have been associated with the subsequent development of lung cancer, of which cigarette smoking is the most important. The risk factors associated with the development of lung cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary risk factor for the development of lung cancer is cigarette smoking, which is estimated to account for approximately 90 percent of all lung cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk of developing lung cancer for a current smoker of one pack per day for 40 years is approximately 20 times that of someone who has never smoked. Factors that increase the risk of developing lung cancer in smokers include the extent of smoking and exposure to other carcinogenic factors, such as asbestos.",
"   </p>",
"   <p>",
"    Thus, the most important aspects of lung cancer prevention are preventing people from starting to smoke and inducing those who already smoke to stop. In individuals who do quit smoking, the risk of developing lung cancer gradually falls for about 15 years before it levels off and remains about twice that of someone who never smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) can increase the risk of a second primary lung cancer in patients who have been treated for other malignancies.",
"   </p>",
"   <p>",
"    In women who receive RT following a mastectomy for breast cancer, there appears to be an increased risk of lung cancer among smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/7\">",
"     7",
"    </a>",
"    ]. In a retrospective tumor registry study of 113 breast cancer patients who had a second primary lung cancer and 364 controls, there was an increased risk of a second primary lung cancer among women who had smoked and received postoperative RT. The risk was more pronounced for cancers in the ipsilateral lung. Similarly, RT for Hodgkin lymphoma has been associated with an increased risk of secondary lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improved RT techniques limit the dose of radiation to nonmalignant tissue, and contemporary equipment and dose planning is thought to significantly reduce the risk for secondary lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other factors may affect the risk of developing lung cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental toxins &mdash; Environmental factors have been associated with an increased risk for developing lung cancer. These include exposure to second-hand smoke, asbestos, radon, metals (arsenic, chromium, and nickel), ionizing radiation, and polycyclic aromatic hydrocarbons [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"       \"Secondhand smoke exposure: Effects in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary fibrosis &mdash; Several studies have shown that the risk for lung cancer is increased about sevenfold patients with pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/10\">",
"       10",
"      </a>",
"      ]. This increased risk appears to be independent of smoking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV infection &mdash; The incidence of lung cancer among individuals infected with HIV appears to be increased compared to that seen in uninfected controls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506361#H1560506361\">",
"       \"HIV infection and malignancy: Management considerations\", section on 'Lung cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic factors &mdash; Genetic factors can affect both the risk for and prognosis from lung cancer. Although the genetic basis of lung cancer is still being elucidated, there is a clearly established familial risk.",
"     </li>",
"     <li>",
"      Dietary factors &mdash; Epidemiologic evidence has suggested that various dietary factors (antioxidants, cruciferous vegetables, phytoestrogens) may reduce the risk of lung cancer, but the role of these factors is not well established. Attempts to confirm these epidemiologic findings and to decrease the incidence of lung cancer in high-risk patients have not been successful. As example, the Alpha-Tocopherol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention Study actually showed an increase in lung cancer among smokers with dietary supplementation of beta-carotene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8902?source=see_link\">",
"       \"Chemoprevention of lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lung cancer is primarily based upon evaluation of individuals with symptoms. Screening for lung cancer has not been widely used, since chest radiography and sputum cytology have not been shown to reduce mortality from lung cancer.",
"   </p>",
"   <p>",
"    Prospective, single-arm observational studies have shown that a large percentage of lung cancers detected by CT screening are early stage tumors, which have a favorable prognosis. These findings led to the randomized National Lung Screening Trial that compared CT screening with chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/11\">",
"     11",
"    </a>",
"    ]. This trial demonstrated a&nbsp;20 percent decrease in&nbsp;lung cancer mortality in heavy smokers who were screened annually for three years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link&amp;anchor=H75373691#H75373691\">",
"     \"Screening for lung cancer\", section on 'National Lung Screening Trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization classification for primary lung cancer recognizes four major histologic cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximate frequencies of these are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma (including bronchioloalveolar carcinoma) &mdash; 38 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56983 \" href=\"UTD.htm?17/17/17687\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81088 \" href=\"UTD.htm?26/1/26644\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Squamous cell carcinoma &mdash; 20 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64310 graphicRef52600 \" href=\"UTD.htm?5/26/5541\">",
"       image 2A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75031 graphicRef55094 graphicRef69956 \" href=\"UTD.htm?33/46/34538\">",
"       picture 1A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Large cell carcinoma &mdash; 5 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82462 \" href=\"UTD.htm?26/24/27009\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef60987 \" href=\"UTD.htm?32/63/33780\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Small cell carcinoma 13 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51958 \" href=\"UTD.htm?3/34/3622\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63799 \" href=\"UTD.htm?6/30/6631\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other non-small cell carcinomas, which cannot be further classified (18 percent)",
"     </li>",
"     <li>",
"      Other (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative incidence of adenocarcinoma has risen dramatically, and there has been a corresponding decrease in the incidence of other types of NSCLC and SCLC. The increased incidence of adenocarcinoma is thought to be due to the introduction of low-tar filter cigarettes in the 1960s, although this relationship is unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with lung cancer have advanced disease at clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef76229 \" href=\"UTD.htm?10/20/10571\">",
"     table 1",
"    </a>",
"    ). This may reflect the aggressive biology of the disease, the frequent absence of symptoms until locally advanced or metastatic disease is present, and the lack of an effective screening test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms may result from local effects of the tumor, from regional or distant spread, or from distant effects not related to metastases (paraneoplastic syndromes). Approximately three-fourths of patients have one or more symptoms at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intrathoracic effects of the cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a wide range of symptoms due to the intrathoracic effects of the cancer, the most common of which are cough, hemoptysis, chest pain, and dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355281935\">",
"    <span class=\"h3\">",
"     Cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough is present in 50 to 75 percent of lung cancer patients at presentation and occurs most frequently in patients with squamous cell and small cell carcinomas, because of their tendency to involve central airways [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The new onset of cough in a smoker or former smoker should raise suspicion that lung cancer is present. Bronchorrhea or cough productive of large volumes of thin, mucoid secretions may be a feature of bronchoalveolar cell carcinoma and usually indicates advanced disease. Both NSCLC and SCLC often cause a post-obstructive pneumonia. However, bronchiectasis is uncommon because lung cancer usually progresses too rapidly for bronchiectasis to develop. In contrast, slow-growing neoplasms such as carcinoid tumor or hamartoma are more likely to present with bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9946?source=see_link\">",
"     \"Bronchioloalveolar carcinoma, including adenocarcinoma in situ\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355281942\">",
"    <span class=\"h3\">",
"     Hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoptysis is reported by 25 to 50 percent of patients who are diagnosed with lung cancer, although bronchitis is the most common cause of this symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Any amount of hemoptysis can be alarming to the patient, and large volumes of hemoptysis may cause asphyxia. In a patient with hemoptysis, the likelihood of lung cancer varies from 3 to 34 percent in different series depending upon the patient's age and smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/16\">",
"     16",
"    </a>",
"    ]. In smokers with hemoptysis and a nonsuspicious or normal chest radiograph, bronchoscopy will diagnose lung cancer in about 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=see_link\">",
"     \"Etiology and evaluation of hemoptysis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355281949\">",
"    <span class=\"h3\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain is present in approximately 20 percent of patients presenting with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. It can be quite variable in character and is more common in younger compared to older patients. Pain is typically present on the same side of the chest as the primary tumor. Dull, aching, persistent pain may occur from mediastinal, pleural, or chest wall extension, but the presence of pain does not necessarily preclude resectability. Although pleuritic pain may be the result of direct pleural involvement, obstructive pneumonitis or a pulmonary embolus related to a hypercoagulable state may also cause chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355281956\">",
"    <span class=\"h3\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortness of breath is a common symptom in patients with lung cancer at the time of diagnosis, occurring in approximately 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Dyspnea may be due to extrinsic or intraluminal airway obstruction, obstructive pneumonitis or atelectasis, lymphangitic tumor spread, tumor emboli, pneumothorax, pleural effusion, or pericardial effusion with tamponade. Partial obstruction of a bronchus may cause a localized wheeze, heard by the patient or by the clinician on auscultation, while stridor can result from obstruction of larger airways.",
"    <br/>",
"    <br/>",
"    Pulmonary function testing may be useful in a patient with dyspnea due to lung cancer, as it may show flattening of the expiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inspiratory flow-volume loop from presence of tumor in the trachea itself (",
"    <a class=\"graphic graphic_figure graphicRef57161 \" href=\"UTD.htm?6/12/6351\">",
"     figure 2",
"    </a>",
"    ), from extrinsic compression, or from vocal cord paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Unilateral paralysis of the diaphragm may be due to damage of the phrenic nerve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75001 \" href=\"UTD.htm?11/21/11601\">",
"     image 5",
"    </a>",
"    ). Patients may be asymptomatic or report shortness of breath. In one series, lung cancer was the most common neoplasm affecting the phrenic nerve, although malignancy accounted for only 4 percent of patients presenting with diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355281963\">",
"    <span class=\"h3\">",
"     Hoarseness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of persistent hoarseness in a smoker includes both laryngeal cancer and lung cancer. In patients with lung cancer, this is due to malignancy involving the recurrent laryngeal nerve along its course under the arch of the aorta and back to the larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=see_link\">",
"     \"Hoarseness in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282026\">",
"    <span class=\"h3\">",
"     Pleural involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension of tumor into the visceral pleura is stage T2 and into the parietal pleura is T3. The presence of carcinoma cells in the pleural fluid classifies the lung cancer as M1a (stage IV) in the seventh edition TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 2",
"    </a>",
"    ). Pleural involvement can manifest as pleural thickening without pleural effusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68407 \" href=\"UTD.htm?40/57/41887\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Patients with malignant effusions are considered incurable and managed palliatively. Although malignant pleural effusions can cause dyspnea and cough, approximately one-fourth of patients who have lung cancer and pleural metastases are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/22\">",
"     22",
"    </a>",
"    ]. Although a malignant pleural effusion precludes curative resection, not all pleural effusions in patients with lung cancer are malignant. A benign pleural effusion may occur in a patient with a resectable lung cancer due to lymphatic obstruction, post-obstructive pneumonitis, or atelectasis. In a patient with a pleural effusion, the presence of tumor needs to be confirmed or excluded so that a chance for curative resection is not missed. Series report that 5 to 14 percent of patients with NSCLC and an ipsilateral pleural effusion have resectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Surgical thoracoscopy or medical pleuroscopy should follow two or three negative cytologies to further evaluate the pleural space prior to surgical resection of a primary lesion.",
"   </p>",
"   <p>",
"    Malignant effusions are typically exudates and may be serous, serosanguineous, or grossly bloody. The yield of pleural fluid cytology after a single thoracentesis in patients with documented pleural involvement is about 60 percent, and the yield rises to 85 percent with three thoracenteses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/25\">",
"     25",
"    </a>",
"    ]. A prospective series evaluated cytologic yield from pleural fluid aliquots of 10 mL, 60 mL, and &ge;150 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/26\">",
"     26",
"    </a>",
"    ]. The sensitivity for diagnosing malignancy in the pleural fluid was lower for volumes of 10 mL compared to the higher volumes. Closed pleural biopsy adds little to the yield of cytologic examination. In a patient with a suspected malignancy, repeat pleural fluid cytology with or without pleural biopsy is appropriate if the initial study is negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the course of their disease, approximately 10 to 15 percent of patients who have lung cancer will have malignant pleural effusions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81680 graphicRef56176 \" href=\"UTD.htm?24/30/25063\">",
"     image 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/27\">",
"     27",
"    </a>",
"    ]. The management of patients with malignant pleural effusions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282033\">",
"    <span class=\"h3\">",
"     Superior vena cava syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the superior vena cava (SVC) causes symptoms that commonly include a sensation of fullness in the head and dyspnea. Cough, pain, and dysphagia are less frequent. Physical findings include dilated neck veins, a prominent venous pattern on the chest, facial edema, and a plethoric appearance (",
"    <a class=\"graphic graphic_picture graphicRef81445 \" href=\"UTD.htm?0/31/500\">",
"     picture 4",
"    </a>",
"    ). The chest radiograph typically shows widening of the mediastinum or a right hilar mass. CT can often identify the cause, level of obstruction, and extent of collateral venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SVC syndrome is more common in patients with SCLC than NSCLC. For most patients who have SVC syndrome secondary to lung cancer, the symptoms resolve after treatment of the mediastinal tumor. The pathophysiology and treatment options for the management of patients with SVC syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282040\">",
"    <span class=\"h3\">",
"     Pancoast's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancers arising in the superior sulcus cause a characteristic Pancoast's syndrome manifested by pain (usually in the shoulder, and less commonly in the forearm, scapula, and fingers), Horner's syndrome, bony destruction, and atrophy of hand muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancoast's syndrome is most commonly caused by NSCLC (typically squamous cell) and only rarely by SCLC (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55842 graphicRef81147 \" href=\"UTD.htm?18/35/18994\">",
"     image 8A-B",
"    </a>",
"    ). The presentation, diagnosis, and treatment of patients with Pancoast's syndrome due to superior sulcus tumors is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"     \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extrathoracic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer can spread to any part of the body tissue. Metastatic spread may result in the presenting symptoms or may occur later in the course of disease.",
"   </p>",
"   <p>",
"    The staging at presentation of patients with known or suspected lung cancer is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent sites of distant metastasis are the liver, adrenal glands, bones, and brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282312\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hepatic metastases are uncommon early in the course of disease. Asymptomatic liver metastases may be detected at presentation by liver enzyme abnormalities, CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58174 \" href=\"UTD.htm?27/27/28085\">",
"     image 9",
"    </a>",
"    ), or PET (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69909 \" href=\"UTD.htm?29/55/30577\">",
"     image 10",
"    </a>",
"    ). Among patients with otherwise resectable NSCLC in the chest, CT evidence of liver metastasis has been identified in approximately 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/29\">",
"     29",
"    </a>",
"    ]. PET or integrated PET-CT identifies unsuspected metastases in the liver or adrenal glands in about 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The incidence of liver metastases is much higher later in the course of the disease. Autopsy studies have shown that hepatic metastases are present in more than 50 percent of patients with either NSCLC or SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282319\">",
"    <span class=\"h3\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastasis from lung cancer to bone is frequently symptomatic. Pain in the back, chest, or extremity, and elevated levels of serum alkaline phosphatase are usually present in patients who have bone metastasis. The serum calcium may be elevated due to extensive bone disease. Approximately 20 percent of patients with NSCLC have bone metastases on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/34\">",
"     34",
"    </a>",
"    ]. An osteolytic radiographic appearance is more frequent than an osteoblastic one, and the most common sites of involvement are the vertebral bodies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73034 \" href=\"UTD.htm?16/49/17170\">",
"     image 11",
"    </a>",
"    ). Bone metastases are even more frequent in SCLC and can be found in 30 to 40 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76532 \" href=\"UTD.htm?30/37/31312\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/35\">",
"     35",
"    </a>",
"    ]. PET and PET-CT have improved the ability to identify metastases to many organs, including bone, with greater sensitivity than CT or bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282326\">",
"    <span class=\"h3\">",
"     Adrenal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are a frequent site of metastasis but such metastases are only rarely symptomatic. Concern about adrenal metastasis usually occurs when a unilateral mass is found by staging CT in a patient with a known or suspected lung cancer. Only a fraction of adrenal masses detected on staging scans represent metastasis. This was illustrated by a series of 330 patients with operable NSCLC, in which 32 (10 percent) had an isolated adrenal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/37\">",
"     37",
"    </a>",
"    ]. Only 8 of these 32 (25 percent) were malignant while the remainder had benign lesions (adenomas, nodular hyperplasia, hemorrhagic cysts). Conversely, a negative imaging study does not exclude adrenal metastases. A study of patients with SCLC found that 17 percent of adrenal biopsies showed metastatic involvement despite having a normal CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of specificity of an initial CT identifying an adrenal mass creates a special problem in patients with an otherwise resectable lung cancer. In this situation, PET may be particularly useful in distinguishing a benign from malignant adrenal mass (",
"    <a class=\"graphic graphic_figure graphicRef64673 \" href=\"UTD.htm?39/43/40624\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/39\">",
"     39",
"    </a>",
"    ]. Other procedures that may be useful in excluding a metastasis include an MRI consistent with a benign adenoma or a negative needle biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the adrenal glands is more frequent in patients with widely disseminated disease. In autopsy series, adrenal gland metastases have been identified in about 40 percent of patients with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282333\">",
"    <span class=\"h3\">",
"     Brain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic manifestations of lung cancer include metastases and paraneoplastic syndromes. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Paraneoplastic phenomena'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms from central nervous system metastasis are similar to those with other tumors and include headache, vomiting, visual field loss, hemiparesis, cranial nerve deficit, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with NSCLC, the frequency of brain metastasis is greatest with adenocarcinoma and least with squamous cell carcinoma. The risk for brain metastasis increases with larger primary tumor size and the presence of regional node involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63227 \" href=\"UTD.htm?9/26/9633\">",
"     image 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/40\">",
"     40",
"    </a>",
"    ]. For carefully selected patients, sequential resection may be feasible in cases that have operable NSCLC in the chest and a solitary brain metastasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with SCLC, metastasis to brain is present in approximately 20 to 30 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/41\">",
"     41",
"    </a>",
"    ]. Without prophylactic irradiation, relapse in the brain occurs in about one-half of patients within two years. Randomized trials have shown that the frequency of brain metastases can be significantly reduced with prophylactic cranial radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Paraneoplastic phenomena",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic effects of tumor are remote effects that are not related to the direct invasion, obstruction, or metastasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282340\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia in patients with lung cancer may arise from a bony metastasis or less commonly tumor secretion of a parathyroid hormone-related protein (PTHrP), calcitriol or other cytokines, including osteoclast activating factors.",
"   </p>",
"   <p>",
"    In one study of 1149 consecutive lung cancers, 6 percent had hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/42\">",
"     42",
"    </a>",
"    ]. Among those with hypercalcemia, squamous cell carcinoma, adenocarcinoma, and SCLC were responsible in 51, 22, and 15 percent of cases, respectively. Most patients with hypercalcemia have advanced disease (stage III or IV) and a median survival of a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of hypercalcemia include anorexia, nausea, vomiting, constipation, lethargy, polyuria, polydipsia, and dehydration. Confusion and coma are late manifestations, as are renal failure and nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients who have serum calcium of 12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or higher require treatment that includes hydration and bisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/43\">",
"     43",
"    </a>",
"    ]. The treatment of hypercalcemia due to malignancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282374\">",
"    <span class=\"h3\">",
"     SIADH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is frequently caused by SCLC and results in hyponatremia. Approximately 10 percent of patients who have SCLC exhibit SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. SCLC accounts for approximately 75 percent of all malignancy-related of SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of symptoms is related to the degree of hyponatremia and the rapidity of the fall in serum sodium. Symptoms include anorexia, nausea, and vomiting. Cerebral edema can occur with the onset of hyponatremia is rapid. Symptoms caused by cerebral edema may include irritability, restlessness, personality changes, confusion, coma, seizures, and respiratory arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of SIADH focuses on treating the malignancy. In the majority of patients with SCLC, the hyponatremia will resolve within weeks of starting chemotherapy. Chronic hyponatremia or that of unclear duration may be treated with normal saline infusion to euvolemia, fluid restriction and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    , or a vasopressin-receptor antagonist. Acute and severe hyponatremia may be carefully treated with hypertonic (3 percent) saline infusion for a correction of 1 to 2 mmol per liter per hour with a correction of not more than 8 to 10 mmol per liter in 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355283224\">",
"    <span class=\"h3\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cancer associated with paraneoplastic neurologic syndromes; typically these are associated with SCLC. Paraneoplastic neurologic syndromes are thought to be immune-mediated, and autoantibodies have been identified in a number of instances. The various neurologic paraneoplastic syndromes and their pathophysiology are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7239?source=see_link\">",
"     \"Paraneoplastic visual syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    These diverse neurologic manifestations include, but are not limited to, Lambert-Eaton myasthenic syndrome (LEMS), cerebellar ataxia, sensory neuropathy, limbic encephalitis, encephalomyelitis, autonomic neuropathy, retinopathy, and opsomyoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common of these is LEMS, which may be seen in approximately 3 percent of patients with SCLC (",
"    <a class=\"graphic graphic_waveform graphicRef62084 \" href=\"UTD.htm?43/48/44804\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/48\">",
"     48",
"    </a>",
"    ]. The neurologic symptoms of LEMS precede the diagnosis of SCLC in more than 80 percent of cases, often by months to years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2744?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of Lambert-Eaton myasthenic syndrome\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As many as 70 percent of patients who have SCLC and an associated paraneoplastic neurologic syndrome have limited stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/49\">",
"     49",
"    </a>",
"    ]. The finding of a paraneoplastic autoantibody in patients presenting with a neurologic syndrome should lead to an evaluation for malignancy. A CT of the chest is indicated in current or former smokers who have a suspected paraneoplastic neurologic syndrome. If the CT chest is negative, then PET may be useful in identifying the location of a neoplasm. Even subtle abnormalities of the lungs or mediastinum require biopsy in this situation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66186 graphicRef75243 \" href=\"UTD.htm?24/57/25493\">",
"     image 14A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paraneoplastic neurologic syndromes generally do not improve with immunosuppressive treatment. However, symptoms may stabilize with response of the underlying neoplasm to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355282953\">",
"    <span class=\"h3\">",
"     Hematologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hematologic abnormalities are seen in patients with lung cancer. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia &mdash; Anemia is frequent in patients with lung cancer and can contribute to fatigue and dyspnea. As an example, in one series 40 percent of untreated patients had a hemoglobin &le;12",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      while the incidence of anemia was 80 percent in those on chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/51\">",
"       51",
"      </a>",
"      ]. Anemia may be due to any of a number of causes, including treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leukocytosis &mdash; In one series, tumor-associated leukocytosis was found in 15 percent of patients with lung cancer. Nearly all had NSCLC, and the leukocytosis was thought to be due to overproduction of granulocyte-colony stimulating factor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/52\">",
"       52",
"      </a>",
"      ]. Leukocytosis in association with lung cancer is associated with a poor prognosis and has also been associated with hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/42,52\">",
"       42,52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link&amp;anchor=H17#H17\">",
"       \"Causes of neutrophilia\", section on 'Secondary neutrophilia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytosis &mdash; Thrombocytosis is common and maybe present in as many as 14 percent of patients with lung cancer at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/53\">",
"       53",
"      </a>",
"      ]. Thrombocytosis at presentation has been identified as an independent predictor of shortened survival [",
"      <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eosinophilia &mdash; Eosinophilia in tissue or blood is rare, but has been reported in patients with large cell carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link&amp;anchor=H17#H17\">",
"       \"Approach to the patient with eosinophilia\", section on 'Hematologic and neoplastic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercoagulable disorders &mdash; A variety of hypercoagulable disorders have been associated with lung cancer and other malignancies. These hypercoagulable disorders include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Trousseau's syndrome (migratory superficial thrombophlebitis)",
"     </li>",
"     <li>",
"      Deep venous thrombosis and thromboembolism",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulopathy",
"     </li>",
"     <li>",
"      Thrombotic microangiopathy",
"     </li>",
"     <li>",
"      Nonthrombotic microangiopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546074770\">",
"    <span class=\"h3\">",
"     Hypertrophic osteoarthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic pulmonary osteoarthropathy (HPO) is defined by the presence of clubbing (",
"    <a class=\"graphic graphic_picture graphicRef71809 \" href=\"UTD.htm?24/48/25346\">",
"     picture 5",
"    </a>",
"    ) and periosteal proliferation of the tubular bones associated with lung cancer or other lung disease. Clinically, HPO is characterized by a symmetrical, painful arthropathy that usually involves the ankles, knees, wrists, and elbows. The metacarpal, metatarsal, and phalangeal bones may also be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    A radiograph of the long bones (ie, tibia and fibula) shows characteristic periosteal new bone formation in patients with HPO. An isotope bone scan or PET typically demonstrates diffuse uptake by the long bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62962 graphicRef72455 \" href=\"UTD.htm?36/23/37236\">",
"     image 15A-B",
"    </a>",
"    ). The symptoms of HPO may resolve after tumor resection. For patients who are not operable, the usual treatment is with nonsteroidal antiinflammatory agents or a bisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546074780\">",
"    <span class=\"h3\">",
"     Dermatomyositis and polymyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis and polymyositis are two distinct forms of inflammatory myopathy, both of which are manifested clinically by muscle weakness. These inflammatory myopathies can be the presenting symptom in patients with lung cancer or can develop later in the course of disease. In addition to lung cancer, other frequent primary sites associated with these disorders include the ovary, cervix, pancreas, bladder, and stomach. The incidence of malignancy and the role of screening for cancer in patients with dermatomyositis or polymyositis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546074787\">",
"    <span class=\"h3\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic production of adrenal corticotropin (ACTH) can cause Cushing's syndrome. Patients typically present with muscle weakness, weight loss, hypertension, hirsutism, and osteoporosis. Hypokalemic alkalosis and hyperglycemia are usually present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Cushing's syndrome is relatively common in patients with SCLC and with carcinoid tumors of the lung, as well as extrathoracic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients with Cushing's syndrome and SCLC appear to have a worse prognosis than patients with SCLC without Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/57/16282/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H14#H14\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Cushing's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       \"Patient information: Lung cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=see_link\">",
"       \"Patient information: Asbestos exposure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cause of cancer mortality worldwide for both men and women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cigarette smoking is responsible for approximately 90 percent of cases of lung cancer. Thus prevention of smoking and cessation of smoking offer the most important route to decreasing the morbidity and mortality associated with this disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"       \"Cigarette smoking and other risk factors for lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung cancer is divided into several histologic types. The most important distinction is between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"       \"Pathology of lung malignancies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical manifestations of lung cancer can be due to intrathoracic effects of the tumor (eg, cough, hemoptysis, pleural disease), extrathoracic metastases (most commonly, liver, bone, brain), or paraneoplastic phenomena (eg, hypercalcemia, Cushing's syndrome, hypercoagulability disorders, various neurologic syndromes). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation, treatment, and prognosis of lung cancer are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"       \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/3\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/4\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/5\">",
"      Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/6\">",
"      Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/7\">",
"      Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/8\">",
"      Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/9\">",
"      Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 2005; 6:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/10\">",
"      Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/11\">",
"      National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.",
"     </a>",
"    </li>",
"    <li>",
"     Travis WD, Brambilla E, M&uuml;ller-Hermelink HK. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart, IARC, Lyon, France 2004.",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/csr/1975_2004/results_merged/sect_15_lung_bronchus.pdf (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/14\">",
"      Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/15\">",
"      Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/16\">",
"      Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/17\">",
"      Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/18\">",
"      Kuo CW, Chen YM, Chao JY, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000; 117:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/19\">",
"      Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/20\">",
"      Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/21\">",
"      Chen HC, Jen YM, Wang CH, et al. Etiology of vocal cord paralysis. ORL J Otorhinolaryngol Relat Spec 2007; 69:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/22\">",
"      Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/23\">",
"      Decker DA, Dines DE, Payne WS, et al. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978; 74:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/24\">",
"      Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg 1999; 68:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/25\">",
"      Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/26\">",
"      Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/27\">",
"      Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med 1998; 19:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/28\">",
"      Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 2006; 59:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/29\">",
"      Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/30\">",
"      van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/31\">",
"      De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/32\">",
"      Stenbygaard LE, S&oslash;rensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol 1997; 36:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/33\">",
"      Jereczek B, Jassem J, Karnicka-Modkowska H, et al. Autopsy findings in small cell lung cancer. Neoplasma 1996; 43:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/34\">",
"      Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123:137S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/35\">",
"      Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/36\">",
"      Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/37\">",
"      Oliver TW Jr, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984; 153:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/38\">",
"      Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol 1983; 140:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/39\">",
"      Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/40\">",
"      Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/41\">",
"      Doyle TJ. Brain metastasis in the natural history of small-cell lung cancer: 1972-1979. Cancer 1982; 50:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/42\">",
"      Hiraki A, Ueoka H, Takata I, et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/43\">",
"      Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol 2004; 5:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/44\">",
"      List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/45\">",
"      Hansen O, S&oslash;rensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/46\">",
"      Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/47\">",
"      Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/48\">",
"      Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/49\">",
"      Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/50\">",
"      Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/51\">",
"      Kosmidis P, Krzakowski M, ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005; 50:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/52\">",
"      Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/53\">",
"      Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005; 60:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/54\">",
"      Aoe K, Hiraki A, Ueoka H, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/55\">",
"      Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/56\">",
"      Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/57\">",
"      Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993; 153:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/57/16282/abstract/58\">",
"      Shepherd FA, Laskey J, Evans WK, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4641 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16282=[""].join("\n");
var outline_f15_57_16282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intrathoracic effects of the cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355281935\">",
"      - Cough",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355281942\">",
"      - Hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355281949\">",
"      - Chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355281956\">",
"      - Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355281963\">",
"      - Hoarseness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282026\">",
"      - Pleural involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282033\">",
"      - Superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282040\">",
"      - Pancoast's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extrathoracic metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282312\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282319\">",
"      - Bone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282326\">",
"      - Adrenal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282333\">",
"      - Brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Paraneoplastic phenomena",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282340\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282374\">",
"      - SIADH secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355283224\">",
"      - Neurologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355282953\">",
"      - Hematologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H546074770\">",
"      - Hypertrophic osteoarthropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H546074780\">",
"      - Dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H546074787\">",
"      - Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4641|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/17/17687\" title=\"diagnostic image 1\">",
"      AdenoCA lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/39/42623\" title=\"diagnostic image 2A\">",
"      Sq cell ca lung CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/50/33568\" title=\"diagnostic image 2B\">",
"      Sq cell ca lung CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/24/27009\" title=\"diagnostic image 3\">",
"      Lg cell ca lung CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/34/3622\" title=\"diagnostic image 4\">",
"      Small cell ca CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/21/11601\" title=\"diagnostic image 5\">",
"      NSCLC hemidiaphragm para",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/57/41887\" title=\"diagnostic image 6\">",
"      NSCLC pleural met PETCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/12/15553\" title=\"diagnostic image 7A\">",
"      NSCLC malig pl eff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/55/12147\" title=\"diagnostic image 7B\">",
"      NSCLC malig pl eff post rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/59/8112\" title=\"diagnostic image 8A\">",
"      Pancoast tumor on CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/29/19934\" title=\"diagnostic image 8B\">",
"      Pancoast tumor PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/27/28085\" title=\"diagnostic image 9\">",
"      NSCLC liver met CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/55/30577\" title=\"diagnostic image 10\">",
"      NSCLC liver met PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/49/17170\" title=\"diagnostic image 11\">",
"      Small cell ca bone met MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/37/31312\" title=\"diagnostic image 12\">",
"      NSCLC bone met PETCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/26/9633\" title=\"diagnostic image 13\">",
"      NSCLC brain met CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/17/39184\" title=\"diagnostic image 14A\">",
"      SCLC normal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/10/12448\" title=\"diagnostic image 14B\">",
"      SCLC pos PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/52/6977\" title=\"diagnostic image 15A\">",
"      Normal bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/10/17583\" title=\"diagnostic image 15B\">",
"      Hyper pul osteo bonescan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4641|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/1/26644\" title=\"figure 1\">",
"      BAC lung CT histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/12/6351\" title=\"figure 2\">",
"      Lg airway obstruct PFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/43/40624\" title=\"figure 3\">",
"      NSCLC adrenal met PETCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4641|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/47/22258\" title=\"picture 1A\">",
"      Sq cell ca lung endobr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/9/5270\" title=\"picture 1B\">",
"      Sq cell ca lung kerat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28870\" title=\"picture 1C\">",
"      Sq cell ca lung keratin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/63/33780\" title=\"picture 2\">",
"      Lg cell ca lung histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/30/6631\" title=\"picture 3\">",
"      Small cell ca histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/31/500\" title=\"picture 4\">",
"      SVC syndrome appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25346\" title=\"picture 5\">",
"      Lung cancer clubbing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/20/10571\" title=\"table 1\">",
"      Presenting symptoms lung ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 2\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4641|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/48/44804\" title=\"waveform 1\">",
"      Lambert Eaton EMG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9946?source=related_link\">",
"      Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=related_link\">",
"      Causes and diagnosis of bilateral diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8902?source=related_link\">",
"      Chemoprevention of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=related_link\">",
"      Hoarseness in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7239?source=related_link\">",
"      Paraneoplastic visual syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=related_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=related_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2744?source=related_link\">",
"      Treatment of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=related_link\">",
"      Women and lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_57_16283="Sx fibromyalgia chronic fatigue";
var content_f15_57_16283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical similarities between fibromyalgia and chronic fatigue syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        80 to 90 percent women, usual age 20 to 55 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgias and fatigue in more than 90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Associated common symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurocognitive and mood disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sleep disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No identifiable cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Testing is normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Physical examination usually normal except for tender points which are required for diagnosis of fibromyalgia and present in most patients with chronic fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal laboratory and radiologic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic symptoms, no highly effective therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16283=[""].join("\n");
var outline_f15_57_16283=null;
var title_f15_57_16284="Lab findings in osteomalacia";
var content_f15_57_16284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in the different causes of osteomalacia and osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum phosphate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum calcium",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum alkaline phosphatase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parathyroid hormone",
"       </td>",
"       <td class=\"subtitle1\">",
"        25-hydroxyvitamin D",
"       </td>",
"       <td class=\"subtitle1\">",
"        1,25-dihydroxyvitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D deficiency",
"       </td>",
"       <td>",
"        &darr; or N",
"       </td>",
"       <td>",
"        &darr; or N",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        N or &uarr; or &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conditions associated with urinary phosphate wasting",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N or &uarr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal renal tubular acidosis",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypophosphatasia",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteogenesis imperfecta and axial osteomalacia",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N or &uarr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        N or &darr;",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: normal; &darr;: reduced; &darr;&darr;: very reduced; &uarr;: elevated.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16284=[""].join("\n");
var outline_f15_57_16284=null;
var title_f15_57_16285="AAST Organ Injury Scales";
var content_f15_57_16285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AAST Organ Injury Scales for stomach, small intestine, colon, and rectum",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Injured structure",
"       </td>",
"       <td class=\"subtitle1\">",
"        AAST grade*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        AIS-90 score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Stomach",
"       </td>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Intramural hematoma &lt;3 cm; partial-thickness laceration",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Intramural hematoma &ge;3 cm; small (&lt;3 cm) laceration",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Large (&gt;3 cm) laceration",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Large laceration involving vessels on greater or lesser curvature",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td>",
"        Extensive (&gt;50 percent) rupture; stomach devascularized",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Small bowel",
"       </td>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Contusion or hematoma without devascularization; partial-thickness laceration",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Small (&lt;50 percent of circumference) laceration",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Large (&ge;50 percent of circumference) laceration without transection",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Transection",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td>",
"        Transection with segmental tissue loss; devascularized segment",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Colon",
"       </td>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Contusion or hematoma; partial-thickness laceration",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Small (&lt;50 percent of circumference) laceration",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Large (&ge;50 percent of circumference) laceration",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Transection",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td>",
"        Transection with tissue loss; devascularized segment",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Rectosigmoid and rectum",
"       </td>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Contusion or hematoma; partial-thickness laceration",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Small (&lt;50 percent of circumference) laceration",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Large (&ge;50 percent of circumference) laceration",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Full-thickness laceration with perineal extension",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td>",
"        Devascularized segment",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIS-90: Abbreviated Injury Score, 1990 version; AAST: American Association for the Surgery of Trauma.",
"     <br>",
"      * Advance one grade for multiple injuries, up to grade III.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weinberg JA, Fabian TC. Injuries to the stomach, small bowel, colon, and rectum. In: ACS Surgery Principles and Practice, 6th Edition, Ashley SA (Ed), BC Decker, 2007. Copyright &copy; 2007 BC Decker.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16285=[""].join("\n");
var outline_f15_57_16285=null;
var title_f15_57_16286="Mediastinal air Boerhaaves";
var content_f15_57_16286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 202px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest film from a patient with Boerhaave's syndrome reveals free mediastinal air along the esophageal contour (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16286=[""].join("\n");
var outline_f15_57_16286=null;
var title_f15_57_16287="Scleral rupture";
var content_f15_57_16287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with 360 degrees of bullous subconjunctival hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient had a history of prior scleral buckle surgery. The patient was found to have a severe posterior scleral rupture that was not closable posteriorly due to extension to the optic nerve on surgical exploration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_57_16287=[""].join("\n");
var outline_f15_57_16287=null;
